{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:35:47Z","timestamp":1769636147298,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40259-014-0108-z","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T06:06:02Z","timestamp":1410156362000},"page":"465-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Elosulfase Alfa: A Review of Its Use in Patients with Mucopolysaccharidosis Type IVA (Morquio A Syndrome)"],"prefix":"10.1007","volume":"28","author":[{"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"issue":"2","key":"108_CR1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10545-007-0529-7","volume":"30","author":"AM Monta\u00f1o","year":"2007","unstructured":"Monta\u00f1o AM, Tomatsu S, Gottesman GS, et al. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis. 2007;30(2):165\u201374.","journal-title":"J Inherit Metab Dis."},{"issue":"1","key":"108_CR2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.01.021","volume":"109","author":"P Harmatz","year":"2013","unstructured":"Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A Clinical Assessment Program: baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab. 2013;109(1):54\u201361.","journal-title":"Mol Genet Metab."},{"issue":"1\u20132","key":"108_CR3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","volume":"110","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Harmatz P, Beck M, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110(1\u20132):54\u201364.","journal-title":"Mol Genet Metab."},{"issue":"2","key":"108_CR4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10545-013-9587-1","volume":"36","author":"TC Wood","year":"2013","unstructured":"Wood TC, Harvey K, Beck M, et al. Diagnosing mucopolysaccharidosis IVA. J Inherit Metab Dis. 2013;36(2):293\u2013307.","journal-title":"J Inherit Metab Dis."},{"issue":"3","key":"108_CR5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajmg.a.20314","volume":"123A","author":"J Nelson","year":"2003","unstructured":"Nelson J, Crowhurst J, Carey B, et al. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A. 2003;123A(3):310\u20133.","journal-title":"Am J Med Genet A."},{"issue":"3","key":"108_CR6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s004390050641","volume":"101","author":"J Nelson","year":"1997","unstructured":"Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet. 1997;101(3):355\u20138.","journal-title":"Hum Genet."},{"issue":"6","key":"108_CR7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","volume":"28","author":"F Baehner","year":"2005","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005;28(6):1011\u20137.","journal-title":"J Inherit Metab Dis."},{"issue":"5","key":"108_CR8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajmg.a.32781","volume":"149A","author":"HY Lin","year":"2009","unstructured":"Lin HY, Lin SP, Chuang CK, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984\u20132004. Am J Med Genet A. 2009;149A(5):960\u20134.","journal-title":"Am J Med Genet A."},{"issue":"11","key":"108_CR9","first-page":"782","volume":"87","author":"H Ben Turkia","year":"2009","unstructured":"Ben Turkia H, Tebib N, Azzouz H, et al. Incidence of mucopolysaccharidoses in Tunisia. Tunis Med. 2009;87(11):782\u20135.","journal-title":"Tunis Med."},{"issue":"1","key":"108_CR10","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1542\/peds.105.1.e10","volume":"105","author":"DA Applegarth","year":"2000","unstructured":"Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969\u20131996. Pediatrics. 2000;105(1):e10.","journal-title":"Pediatrics."},{"issue":"1\u20132","key":"108_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1\u20132):151\u20136.","journal-title":"Hum Genet."},{"issue":"2","key":"108_CR12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87\u201392.","journal-title":"Eur J Hum Genet."},{"key":"108_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00256-013-1797-y","volume":"43","author":"RS Lachman","year":"2014","unstructured":"Lachman RS, Burton BK, Clarke LA, et al. Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux\u2013Lamy syndrome): under-recognized and challenging to diagnose. Skeletal Radiol. 2014;43:359\u201369.","journal-title":"Skeletal Radiol."},{"issue":"6","key":"108_CR14","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/humu.20257","volume":"26","author":"S Tomatsu","year":"2005","unstructured":"Tomatsu S, Monta\u00f1o AM, Nishioka T, et al. Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A). Hum Mutat. 2005;26(6):500\u201312.","journal-title":"Hum Mutat."},{"issue":"5","key":"108_CR15","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","volume":"423","author":"Y Rivera-Colon","year":"2012","unstructured":"Rivera-Colon Y, Schutsky EK, Kita AZ, Garman SC. The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A. J Mol Biol. 2012;423(5):736\u201351.","journal-title":"J Mol Biol."},{"issue":"2","key":"108_CR16","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ymgme.2014.03.004","volume":"112","author":"A Morrone","year":"2014","unstructured":"Morrone A, Tylee KL, Al-Sayed M, et al. Molecular testing of 163 patients with Morquio A (Mucopolysaccharidosis IVA) identifies 39 novel GALNS mutations. Mol Genet Metab. 2014;112(2):160\u201370.","journal-title":"Mol Genet Metab."},{"issue":"1","key":"108_CR17","first-page":"45","volume":"9","author":"MF Algahim","year":"2013","unstructured":"Algahim MF, Almassi GH. Current and emerging management options for patients with Morquio A syndrome. Ther Clin Risk Manag. 2013;9(1):45\u201353.","journal-title":"Ther Clin Risk Manag."},{"issue":"2","key":"108_CR18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-013-9586-2","volume":"36","author":"GA Solanki","year":"2013","unstructured":"Solanki GA, Martin KW, Theroux MC, et al. Spinal involvement in mucopolysaccharidosis IVA (Morquio-Brailsford or Morquio A syndrome): presentation, diagnosis and management. J Inherit Metab Dis. 2013;36(2):339\u201355.","journal-title":"J Inherit Metab Dis."},{"issue":"4","key":"108_CR19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11832-014-0601-4","volume":"8","author":"KK White","year":"2014","unstructured":"White KK, Jester A, Bache CE, et al. Orthopedic management of the extremities in patients with Morquio A syndrome. J Child Orthop. 2014;8(4):295\u2013304.","journal-title":"J Child Orthop."},{"issue":"2","key":"108_CR20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10545-012-9459-0","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Al-Jawad M, Berger KI, et al. Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA. J Inherit Metab Dis. 2013;36(2):309\u201322.","journal-title":"J Inherit Metab Dis."},{"issue":"6","key":"108_CR21","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183\u201397.","journal-title":"J Inherit Metab Dis."},{"issue":"6","key":"108_CR22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","volume":"12","author":"S Tomatsu","year":"2011","unstructured":"Tomatsu S, Montano AM, Oikawa H, et al. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment. Curr Pharm Biotechnol. 2011;12(6):931\u201345.","journal-title":"Curr Pharm Biotechnol."},{"key":"108_CR23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1750-1172-9-32","volume":"9","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32. doi: 10.1186\/1750-1172-9-32 .","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"108_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10545-011-9430-5","volume":"36","author":"JE Davison","year":"2013","unstructured":"Davison JE, Kearney S, Horton J, et al. Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J Inherit Metab Dis. 2013;36(2):323\u20138.","journal-title":"J Inherit Metab Dis."},{"key":"108_CR25","unstructured":"Lavery C, Hendriksz C. Mortality in patients with Morquio syndrome A. JIMD Rep. [Epub 10 Apr 2014]."},{"key":"108_CR26","doi-asserted-by":"crossref","unstructured":"Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2104. doi: 10.1007\/s10545-014-9715-6 [Epub 9 May 2014].","DOI":"10.1007\/s10545-014-9715-6"},{"issue":"Suppl 2","key":"108_CR27","first-page":"S303","volume":"36","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Vellodi A, Jones S, et al. A multicenter, open-label, extension study to evaluate the long-term efficacy and safety of BMN110 in patients with mucopolysaccharidosis IVA (MPS IVA, Morquio A syndrome) [abstract no. P-733]. J Inherit Metab Dis. 2013;36(Suppl 2):S303.","journal-title":"J Inherit Metab Dis."},{"key":"108_CR28","unstructured":"Qi Y, Musson D, Martell L, et al. Phase 1\/2 pharmacokinetic studies of recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) in MPS IVA patients [abstract]. In: American Association of Pharmaceutical Scientists Annual Meeting; 14\u201318 Oct 2012; Chicago (IL)."},{"key":"108_CR29","unstructured":"Qi Y, Musson D, Tompkins T, et al. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase 3 trial [abstract no. 76]. In: American College of Medical Genetics 2014 Annual Clinical Genetics Meeting; 25\u201329 Mar 2014; Nashville (TN)."},{"issue":"2","key":"108_CR30","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ymgme.2011.11.105","volume":"105","author":"F Lorget","year":"2012","unstructured":"Lorget F, Lee S, Lau K, et al. BMN 110 (recombinant human GALNS), an investigational enzyme replacement therapy for mucopolysaccharidosis type iva (MPS IVA or morquio syndrome), promotes type II collagen synthesis in MPS IVA patients [abstract]. Mol Genet Metab. 2012;105(2):S44.","journal-title":"Mol Genet Metab."},{"key":"108_CR31","unstructured":"Harmatz P, Jones S, Bialer M, et al. Safety and pharmacodynamic activity of elosulfase alfa in pediatric patients less than 5 years of age with Morquio A syndrome (mucopolysaccharidosis IVA) [abstract]. In: 13th International Symposium on Mucopolysaccaridoses and Related Diseases; 13\u201317 Aug 2014; Costa do Sauipe, Brazil."},{"key":"108_CR32","unstructured":"Vimizim (elosulfase alfa) 1\u00a0mg\/mL concentrate for solution for infusion: summary of product characteristics. London: European Medicines Agency; 2014."},{"key":"108_CR33","unstructured":"Vimizim (elosulfase alfa) injection, for intravenous use: US prescribing information. Novato (CA): Biomarin Pharmaceutical Inc.; 2014."},{"issue":"8","key":"108_CR34","doi-asserted-by":"crossref","first-page":"e12194","DOI":"10.1371\/journal.pone.0012194","volume":"5","author":"M Dvorak-Ewell","year":"2010","unstructured":"Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One. 2010;5(8):e12194. doi: 10.1371\/journal.pone.0012194 .","journal-title":"PLoS One."},{"key":"108_CR35","doi-asserted-by":"crossref","unstructured":"Harmatz P, Hendriksz CJ, Giugliani R, et al. Long term safety analysis of BMN110 dosed at 2 mg\/kg\/week in 52 subjects with mucopolysaccharidosis (Morquio A syndrome, MPSIVA) [abstract no. P-732]. J Inherit Metab Dis. 2013;36(Suppl 2): S303. Plus poster presented at the 12th International Congress of Inborn Errors of Metabolism; 3\u20136 Sep 2013; Barcelona.","DOI":"10.1007\/s10545-013-9635-x"},{"key":"108_CR36","unstructured":"Edano C, Malick M, Burton B. Infusion management of elosulfase alfa for patients with Morquio A syndrome [abstract]. In: 13th International Symposium on Mucopolysaccharidoses and Related Diseases; 13\u201317 Aug 2014; Costa Do Sauipe, Brazil."},{"issue":"3","key":"108_CR37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/mus.23905","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357\u201368.","journal-title":"Muscle Nerve."},{"issue":"3","key":"108_CR38","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01823246-201324030-00004","volume":"24","author":"MK Shoemaker","year":"2013","unstructured":"Shoemaker MK, Curtis AB, Vangsnes E, et al. Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure. Cardiopulm Phys Ther J. 2013;24(3):21\u20139.","journal-title":"Cardiopulm Phys Ther J."},{"issue":"5","key":"108_CR39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1164\/rccm.201203-0480OC","volume":"186","author":"SC Mathai","year":"2012","unstructured":"Mathai SC, Puhan MA, Lam D, et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(5):428\u201333.","journal-title":"Am J Respir Crit Care Med."},{"issue":"2","key":"108_CR40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/thx.2009.113498","volume":"65","author":"JJ Swigris","year":"2010","unstructured":"Swigris JJ, Wamboldt FS, Behr J, et al. The six-minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010;65(2):173\u20137.","journal-title":"Thorax."},{"key":"108_CR41","doi-asserted-by":"crossref","unstructured":"Henricson E, Abresch R, Han JJ, et al. The 6-minute walk test and person-reported outcomes in boys with Duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr. 2013;5. doi: 10.1371\/currents.md.9e17658b007eb79fcd6f723089f79e06 .","DOI":"10.1371\/currents.md.9e17658b007eb79fcd6f723089f79e06"},{"key":"108_CR42","doi-asserted-by":"crossref","unstructured":"Graham S, Waite A, Loba-Olopade O, et al. The Morquio A Registry Study (MARS): improving the understanding of Morquio A syndrome [abstract]. In: Annual Society for the Study of Inborn Errors of Metabolism Symposium; 2\u20135 Sep 2014; Innsbruck.","DOI":"10.1016\/j.ymgme.2014.12.098"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0108-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-014-0108-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0108-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T15:23:34Z","timestamp":1565796214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-014-0108-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["108"],"URL":"https:\/\/doi.org\/10.1007\/s40259-014-0108-z","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}